What makes IBD medically refractory

the retrieved corpus does not provide an explicit, standardized definition of "medically refractory" IBD, one review states plainly that refractory disease status is difficult to define, noting patients may perceive their disease as intractable because of symptom-related loss of daily function even short of objective failure ¹. in practice the term is applied operationally as failure of medical therapy including systemic biologics: e.g. patients "refractory to all medical therapy including systemic infliximab" ² or "treatment-refractory" after exhausting available agents ³, at which point refractory disease becomes an indication for elective surgery ^1,4. ^1,2,4

What is known:

• Refractory disease status to medical treatment is listed as an indicator for elective surgery, but the review explicitly notes it is difficult to define. ¹
• In operational use, patients are labeled refractory when disease persists despite all medical therapy including systemic infliximab. ²
• Fecal diversion and other surgery remain options for refractory CD/UC when medical management fails. ⁴

What is unknown / caveats:

• No formal diagnostic criteria or scoring index for 'refractory' retrieved
• Excerpts use the term descriptively, not as a defined threshold
• The corpus applies "medically refractory" descriptively rather than defining objective criteria (e.g., number of failed agents, endoscopic/histologic thresholds).

References

1. Baik SH, Kim WH. A comprehensive review of inflammatory bowel disease focusing on surgical management. J Korean Soc Coloproctol. 2012;28(3):121-31. PMID: 22816055.

2. Swaminath A, Lichtiger S. Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis. Inflamm Bowel Dis. 2008;14(2):213-6. PMID: 18022870.

3. McDonald GB, Landsverk OJB, McGovern DPB, Aasebø A, Paulsen V, Haritunians T, Reims HM, McLaughlin BM, Zisman T, Li D, Elholm ETMM, Jahnsen FL, Georges GE, Gedde-Dahl T. Allogeneic bone marrow transplantation for patients with treatment-refractory Crohn's Disease. Heliyon. 2024;10(1):e24026. PMID: 38283244.

4. Wang X, Shen B. Management of Crohn's Disease and Complications in Patients With Ostomies. Inflamm Bowel Dis. 2018;24(6):1167-1184. PMID: 29722891.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.